Mizuho Markets Americas LLC Sells 15,116 Shares of Haemonetics Co. (NYSE:HAE)

Mizuho Markets Americas LLC reduced its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 4.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 348,478 shares of the medical instruments supplier's stock after selling 15,116 shares during the quarter. Mizuho Markets Americas LLC owned approximately 0.68% of Haemonetics worth $28,011,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. ProShare Advisors LLC grew its holdings in Haemonetics by 4.7% during the 1st quarter. ProShare Advisors LLC now owns 11,490 shares of the medical instruments supplier's stock worth $981,000 after acquiring an additional 516 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in Haemonetics by 15.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,475 shares of the medical instruments supplier's stock worth $1,363,000 after purchasing an additional 2,160 shares during the last quarter. Edgestream Partners L.P. bought a new position in Haemonetics in the 1st quarter valued at $1,723,000. Covestor Ltd raised its position in shares of Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier's stock worth $58,000 after acquiring an additional 438 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its stake in shares of Haemonetics by 13.2% during the first quarter. CANADA LIFE ASSURANCE Co now owns 50,728 shares of the medical instruments supplier's stock valued at $4,330,000 after acquiring an additional 5,933 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Down 1.7 %

Shares of HAE traded down $1.53 on Friday, hitting $89.22. The company's stock had a trading volume of 564,401 shares, compared to its average volume of 555,780. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of 37.02, a P/E/G ratio of 1.43 and a beta of 0.32. The firm's fifty day moving average price is $77.55 and its 200-day moving average price is $82.75. Haemonetics Co. has a fifty-two week low of $70.25 and a fifty-two week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm's revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.99 earnings per share. On average, equities research analysts expect that Haemonetics Co. will post 4.59 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HAE. Barrington Research reiterated an "outperform" rating and issued a $108.00 price objective on shares of Haemonetics in a research report on Friday, November 8th. Citigroup lowered their price target on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a research report on Thursday, August 22nd. Needham & Company LLC restated a "buy" rating and issued a $112.00 price objective on shares of Haemonetics in a report on Friday. BTIG Research assumed coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a "buy" rating and a $112.00 target price for the company. Finally, Raymond James upgraded Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price target on the stock in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.